JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease ...
Investor's Business Daily on MSN
How This Amgen Rival, Up 33%, Plans To Shake Its Grip In Thyroid Eye Disease
Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results